Overview for the New York Pharma Forum November 12, 2012 Company - PowerPoint PPT Presentation

Overview for the New York Pharma Forum November 12, 2012

Company & Employees • Founded 6 years ago • Located in Massachusetts • 31 employees • Experienced leadership Collectively more than 200 years of device development experience at Boston Scientific, Medtronic, Genzyme, and others 2

480 Biomedical’s Management Team • Duke Collier, CEO • Blaine McKee, Ph.D., Executive VP, CBO • Maria Palasis, Ph.D., Executive VP, CTO • Raymond Knox, VP Operations • Wendy Naimark, Ph.D., Director R&D 3

480 Biomedical’s Board • Carmichael Roberts, Ph.D., Chairman • Duke Collier, CEO • George Whitesides, Ph.D., Harvard University • Bob Langer, Sc.D., MIT • Terry McGuire, Polaris Venture Partners • Jimmy Rosen, Intersouth Partners • Guido Neels, former Guidant COO • Tony Semedo, Medtronic Investors: Polaris, North Bridge, Intersouth, and Medtronic 4

480 Biomedical ’s Lead Product: A Transformational Bioresorbable Scaffold 5

WW SFA Disease Prevalence >12MM 5.5M PAD 8.5M PAD 9.5M PAD 2.8M SFA 4.7M SFA 4.9M SFA Source: DataMonitor Pipeline Perspectives: PAD 2007; internal estimates 6

Major Players are Active in the Space • Acquired DEB • Acquired EV3 in • Developing an SFA company Lutonix July 2010 for bioresorbable in Dec 2011 for $2.6B, strong scaffold $225M + $100M peripheral portfolio earnouts • Abandoning coronary • Purchased Invatec in April stents, but investing in 2010 for $350M plus peripheral interventions $150M in earnouts, has leading DEB for periphery 7

Current SFA Treatments are Suboptimal SFA Treatment Landscape Higher Effectiveness Surgical Bypass Stents Atherectomy Balloon Angioplasty Medical Lower Management Lower Higher Invasiveness 8

Attributes of the the Optimal SFA Stent • Strong – Scaffolds the vessel during healing • Flexible – Responds to vessel motion • Bioresorbable – There only while its needed – Safely resorbed by the body 9

Bioresorbable Scaffolds are Optimal for SFA Drug-Eluting Drug-Eluting Bioresorbable Balloon Stent Scaffold Ease of ✓ ✓ ✓ Procedure Supports vessel ✓ ✓ during healing No Permanent ✓ ✓ Implant 10

Stanza TM : A Superior Bioresorbable Absorption Device Image Strength Flexibility Time ABSORB TM Abbott Similar to metal Highly rigid 3-4 years Vascular stents IGAKI-TAMAI Kyoto Medical Planning Low radial Semi-rigid 3-4 years strength Stanza TM Similar to metal Highly flexible ~1 year 480 Biomedical stents Elongates with vessel =most desirable =least desirable 11

STANCE Trial A Safety Assessment of the Stanza TM Self- Expanding Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions 12

Stanza TM Scaffold Supports Drug Delivery No Drug Drug-Eluting Drug-eluting scaffold in advanced preclinical testing 13

Stanza TM Can be Used to Treat Other Vessels and Lumens in the Body Sinus Coronary Airway Other Arteries GI Below the Knee 14

Overview for the New York Pharma Forum November 12, 2012